Company intelligence / Profile preview

Physiogenex

Escalquens, Occitanie, France

Ownership: Private
Development stage: Other

Overview

Physiogenex is a preclinical contract research organization (CRO) specializing in metabolic disorders, with over 20 years of experience in developing and validating in vivo and ex vivo preclinical models. The company supports drug discovery and development programs for biopharmaceutical, nutraceutical, and agrifood clients, focusing on obesity, diabetes, NASH/MASH, fibrosis, diabetic nephropathy, cardiovascular diseases, dyslipidemia, and atherosclerosis. Physiogenex is known for its high customer satisfaction rate and collaborates with >100 companies globally[1][3][4].

Therapeutic areas: NephrologyCardiovascularEndocrinologyGastroenterologyOther
Modalities: Small moleculePeptideGene therapyProtein
Industry: Drug Discovery Services

Partnerships

Genflow BiosciencesiLEADS BMSHepaRegenix

Beyond the preview

Go deeper on Physiogenex.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Physiogenex.

Explore the full profile